JP2012529434A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012529434A5 JP2012529434A5 JP2012514225A JP2012514225A JP2012529434A5 JP 2012529434 A5 JP2012529434 A5 JP 2012529434A5 JP 2012514225 A JP2012514225 A JP 2012514225A JP 2012514225 A JP2012514225 A JP 2012514225A JP 2012529434 A5 JP2012529434 A5 JP 2012529434A5
- Authority
- JP
- Japan
- Prior art keywords
- increased
- dopamine
- metabolic
- metabolic disorders
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 13
- 208000030159 metabolic disease Diseases 0.000 claims 12
- 230000001965 increasing effect Effects 0.000 claims 11
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims 6
- 229960002802 bromocriptine Drugs 0.000 claims 5
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical group C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 4
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 229960003638 dopamine Drugs 0.000 claims 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 3
- 229940096895 Dopamine D2 receptor agonist Drugs 0.000 claims 2
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 claims 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 102000004877 Insulin Human genes 0.000 claims 2
- 108090001061 Insulin Proteins 0.000 claims 2
- 208000001280 Prediabetic State Diseases 0.000 claims 2
- 239000002288 dopamine 2 receptor stimulating agent Substances 0.000 claims 2
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 235000021588 free fatty acids Nutrition 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- 229940125396 insulin Drugs 0.000 claims 2
- 230000000291 postprandial effect Effects 0.000 claims 2
- 201000009104 prediabetes syndrome Diseases 0.000 claims 2
- 229940044601 receptor agonist Drugs 0.000 claims 2
- 239000000018 receptor agonist Substances 0.000 claims 2
- 150000003626 triacylglycerols Chemical class 0.000 claims 2
- 230000002618 waking effect Effects 0.000 claims 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims 1
- QHZUABXEBRGBLP-LKWYKXIFSA-N (6aR,9R,10aR)-N-[(2R,4R,9aS,9bR)-4-benzyl-9b-hydroxy-3,5-dioxo-2-propan-2-yl-3a,4,7,8,9,9a-hexahydrofuro[3,2-g]indolizin-2-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide (6aR,9R,10aR)-N-[(2R,4R,9aS,9bR)-9b-hydroxy-3,5-dioxo-2,4-di(propan-2-yl)-3a,4,7,8,9,9a-hexahydrofuro[3,2-g]indolizin-2-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide (6aR,10aR)-N-[(2S,4S,9bS)-9b-hydroxy-4-(2-methylpropyl)-3,5-dioxo-2-propan-2-yl-3a,4,7,8,9,9a-hexahydrofuro[3,2-g]indolizin-2-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide methanesulfonic acid Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.CS(O)(=O)=O.C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)C4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)C(C)C)C(C)C)=C3C2=CNC3=C1.C1=CC([C@H]2CC(CN(C)[C@@H]2C2)C(=O)N[C@@]3(C(=O)C4[C@@H](C(N5CCCC5[C@@]4(O)O3)=O)CC(C)C)C(C)C)=C3C2=CNC3=C1.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](C(C21)=O)(NC(=O)[C@H]1CN(C)[C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C(C)C)C1=CC=CC=C1 QHZUABXEBRGBLP-LKWYKXIFSA-N 0.000 claims 1
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 claims 1
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 claims 1
- 102000006969 5-HT2B Serotonin Receptor Human genes 0.000 claims 1
- 108010072584 5-HT2B Serotonin Receptor Proteins 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 claims 1
- 208000032841 Bulimia Diseases 0.000 claims 1
- 206010006550 Bulimia nervosa Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 101150049660 DRD2 gene Proteins 0.000 claims 1
- 102000003779 Dipeptidyl-peptidases and tripeptidyl-peptidases Human genes 0.000 claims 1
- 108090000194 Dipeptidyl-peptidases and tripeptidyl-peptidases Proteins 0.000 claims 1
- 206010048554 Endothelial dysfunction Diseases 0.000 claims 1
- 208000004930 Fatty Liver Diseases 0.000 claims 1
- 102100039994 Gastric inhibitory polypeptide Human genes 0.000 claims 1
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 claims 1
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 claims 1
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 102000015779 HDL Lipoproteins Human genes 0.000 claims 1
- 108010010234 HDL Lipoproteins Proteins 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010019708 Hepatic steatosis Diseases 0.000 claims 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 229940122199 Insulin secretagogue Drugs 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 229940122344 Peptidase inhibitor Drugs 0.000 claims 1
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 claims 1
- 108010026951 Short-Acting Insulin Proteins 0.000 claims 1
- 229940123958 Short-acting insulin Drugs 0.000 claims 1
- 229940123464 Thiazolidinedione Drugs 0.000 claims 1
- 230000003187 abdominal effect Effects 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 230000003915 cell function Effects 0.000 claims 1
- 230000008809 cell oxidative stress Effects 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- PBKVEOSEPXMKDN-LZHUFOCISA-N chembl2311030 Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.CS(O)(=O)=O.CS(O)(=O)=O.C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)C(C)C)C(C)C)=C3C2=CNC3=C1.C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)C(C)CC)C(C)C)=C3C2=CNC3=C1.C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)CC(C)C)C(C)C)=C3C2=CNC3=C1.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](C(N21)=O)(NC(=O)[C@H]1CN(C)[C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C(C)C)C1=CC=CC=C1 PBKVEOSEPXMKDN-LZHUFOCISA-N 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 230000035487 diastolic blood pressure Effects 0.000 claims 1
- 230000003291 dopaminomimetic effect Effects 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 230000008694 endothelial dysfunction Effects 0.000 claims 1
- 230000005713 exacerbation Effects 0.000 claims 1
- 208000010706 fatty liver disease Diseases 0.000 claims 1
- 230000002641 glycemic effect Effects 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 1
- 201000008980 hyperinsulinism Diseases 0.000 claims 1
- 208000020346 hyperlipoproteinemia Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000003914 insulin secretion Effects 0.000 claims 1
- 210000001596 intra-abdominal fat Anatomy 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 229960003587 lisuride Drugs 0.000 claims 1
- 235000012054 meals Nutrition 0.000 claims 1
- 229950004994 meglitinide Drugs 0.000 claims 1
- 229960000698 nateglinide Drugs 0.000 claims 1
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 claims 1
- 229960002748 norepinephrine Drugs 0.000 claims 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 claims 1
- 229960002354 repaglinide Drugs 0.000 claims 1
- 239000003421 short acting drug Substances 0.000 claims 1
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 1
- 230000035488 systolic blood pressure Effects 0.000 claims 1
- 201000005665 thrombophilia Diseases 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21790609P | 2009-06-05 | 2009-06-05 | |
| US61/217,906 | 2009-06-05 | ||
| PCT/US2010/037605 WO2010141938A1 (en) | 2009-06-05 | 2010-06-07 | Combination of dopamine agonists plus first phase insulin secretagouges for the treatment of metabolic disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015168929A Division JP2016026168A (ja) | 2009-06-05 | 2015-08-28 | 代謝障害の治療のためのドーパミン作動薬と第一相インスリン分泌促進薬の組合せ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012529434A JP2012529434A (ja) | 2012-11-22 |
| JP2012529434A5 true JP2012529434A5 (OSRAM) | 2013-07-18 |
| JP5883382B2 JP5883382B2 (ja) | 2016-03-15 |
Family
ID=43298211
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012514225A Active JP5883382B2 (ja) | 2009-06-05 | 2010-06-07 | 代謝障害の治療のためのドーパミン作動薬と第一相インスリン分泌促進薬の組合せ |
| JP2015168929A Withdrawn JP2016026168A (ja) | 2009-06-05 | 2015-08-28 | 代謝障害の治療のためのドーパミン作動薬と第一相インスリン分泌促進薬の組合せ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015168929A Withdrawn JP2016026168A (ja) | 2009-06-05 | 2015-08-28 | 代謝障害の治療のためのドーパミン作動薬と第一相インスリン分泌促進薬の組合せ |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8877708B2 (OSRAM) |
| EP (2) | EP2437732B1 (OSRAM) |
| JP (2) | JP5883382B2 (OSRAM) |
| CN (1) | CN102458376A (OSRAM) |
| AU (1) | AU2010256366B2 (OSRAM) |
| BR (1) | BRPI1009619B8 (OSRAM) |
| ES (1) | ES2682644T3 (OSRAM) |
| WO (1) | WO2010141938A1 (OSRAM) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9655865B2 (en) | 2002-07-29 | 2017-05-23 | Veroscience, Llc | Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes |
| US8821915B2 (en) | 2002-08-09 | 2014-09-02 | Veroscience, Llc | Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders |
| EP2217073B1 (en) | 2007-06-21 | 2019-10-09 | VeroScience LLC | Method of treating metabolic disorders and depression with dopamine receptor agonists |
| US20100035886A1 (en) | 2007-06-21 | 2010-02-11 | Veroscience, Llc | Parenteral formulations of dopamine agonists |
| US8741918B2 (en) | 2007-06-21 | 2014-06-03 | Veroscience Llc | Parenteral formulations of dopamine agonists |
| US9352025B2 (en) | 2009-06-05 | 2016-05-31 | Veroscience Llc | Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders |
| US8431155B1 (en) * | 2012-04-30 | 2013-04-30 | Veroscience Llc | Bromocriptine formulations |
| EP3925610A1 (en) | 2016-04-20 | 2021-12-22 | VeroScience LLC | Composition and method for treating metabolic disorders |
| HRP20241365T1 (hr) | 2017-10-18 | 2024-12-20 | Veroscience Llc | Poboljšane formulacije bromokriptina |
| US11607455B2 (en) | 2019-09-23 | 2023-03-21 | Veroscience Llc | Method for inducing tumor regression |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5614492A (en) * | 1986-05-05 | 1997-03-25 | The General Hospital Corporation | Insulinotropic hormone GLP-1 (7-36) and uses thereof |
| US6004972A (en) * | 1988-05-10 | 1999-12-21 | The Board Of Supervisiors Of Louisiana State University And Agricultural And Mechanical College | Therapeutic process for the treatment of the pathologies of type II diabetes |
| US5468755A (en) | 1988-05-10 | 1995-11-21 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Therapeutic process for the treatment of the pathologies of Type II diabetes |
| US20010016582A1 (en) * | 1997-04-28 | 2001-08-23 | Anthony H. Cincotta | Method and composition for the treatment of lipid and glucose metabolism disorders |
| ES2283025T3 (es) | 1996-08-30 | 2007-10-16 | Novo Nordisk A/S | Derivados de glp-1.1. |
| US20030087820A1 (en) * | 1999-01-14 | 2003-05-08 | Young Andrew A. | Novel exendin agonist formulations and methods of administration thereof |
| DE60036367T2 (de) * | 1999-06-21 | 2008-05-29 | Eli Lilly And Co., Indianapolis | Synergitische verwendung von thiazolidinedionen und glucagon-ähnlichem peptid-1 und dessen agonisten für die behandlung von nicht-insulin-abhängigen diabetes |
| US9655865B2 (en) | 2002-07-29 | 2017-05-23 | Veroscience, Llc | Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes |
| US20080200453A1 (en) | 2002-07-29 | 2008-08-21 | Cincotta Anthony H | Methods of treating metabolic syndrome using dopamine receptor agonists |
| US20070149451A1 (en) | 2003-11-17 | 2007-06-28 | Holmes David G | Combination of a dpp IV inhibitor and an antiobesity or appetite regulating agent |
| US8410047B2 (en) * | 2004-06-11 | 2013-04-02 | Novo Nordisk A/S | Counteracting drug-induced obesity using GLP-1 agonists |
| US8741918B2 (en) * | 2007-06-21 | 2014-06-03 | Veroscience Llc | Parenteral formulations of dopamine agonists |
-
2010
- 2010-06-07 AU AU2010256366A patent/AU2010256366B2/en active Active
- 2010-06-07 US US13/375,810 patent/US8877708B2/en active Active
- 2010-06-07 EP EP10784223.9A patent/EP2437732B1/en active Active
- 2010-06-07 ES ES10784223.9T patent/ES2682644T3/es active Active
- 2010-06-07 BR BRPI1009619A patent/BRPI1009619B8/pt active IP Right Grant
- 2010-06-07 WO PCT/US2010/037605 patent/WO2010141938A1/en not_active Ceased
- 2010-06-07 CN CN2010800280106A patent/CN102458376A/zh active Pending
- 2010-06-07 JP JP2012514225A patent/JP5883382B2/ja active Active
- 2010-06-07 EP EP18169183.3A patent/EP3375437A1/en not_active Withdrawn
-
2015
- 2015-08-28 JP JP2015168929A patent/JP2016026168A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012529434A5 (OSRAM) | ||
| Kikuchi et al. | Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus | |
| del Olmo-Garcia et al. | GLP‐1 receptor agonists and cardiovascular disease in patients with type 2 diabetes | |
| Rosak et al. | Critical evaluation of the role of acarbose in the treatment of diabetes: patient considerations | |
| AU2012328388B2 (en) | Treatment protocol of diabetes type 2 | |
| D'Alessio et al. | Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes | |
| Irons et al. | Drug treatment of type 2 diabetes mellitus in patients for whom metformin is contraindicated | |
| Kang | GPR119 agonists: a promising approach for T2DM treatment? A SWOT analysis of GPR119 | |
| US20150018360A1 (en) | Compositions and methods for treating metabolic disorders | |
| Liu et al. | Cyclobutane derivatives as novel nonpeptidic small molecule agonists of glucagon-like peptide-1 receptor | |
| US20180000768A1 (en) | Intestinal fxr agonism enhances glp-1 signaling to restore pancreatic beta cell functions | |
| Blonde et al. | Comparison of liraglutide versus other incretin‐related anti‐hyperglycaemic agents | |
| JP2015164964A5 (OSRAM) | ||
| JP2018505859A5 (OSRAM) | ||
| Tan et al. | Evogliptin: a new dipeptidyl peptidase inhibitor for the treatment of type 2 diabetes | |
| MX2015003705A (es) | Agente terapeutico para dislipidemia. | |
| JP2023116697A (ja) | 重度のインスリン抵抗性糖尿病の対象における糖尿病の治療方法 | |
| JP2016026168A (ja) | 代謝障害の治療のためのドーパミン作動薬と第一相インスリン分泌促進薬の組合せ | |
| Shao et al. | Synthesis and clinical application of representative small-molecule dipeptidyl Peptidase-4 (DPP-4) inhibitors for the treatment of type 2 diabetes mellitus (T2DM) | |
| Claus et al. | Dual-acting peptide with prolonged glucagon-like peptide-1 receptor agonist and glucagon receptor antagonist activity for the treatment of type 2 diabetes | |
| Ma et al. | Research progress on the GIP/GLP‐1 receptor coagonist tirzepatide, a rising star in type 2 diabetes | |
| KR102595034B1 (ko) | 비알코올성 지방간 질환을 치료하기 위한 5-[[4-[2-[5-(1-하이드록시에틸)피리딘-2-일]에톡시]페닐]메틸]-1,3-티아졸리딘-2,4-디온 | |
| Howell et al. | Clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to date | |
| Li et al. | GLP-1R in diabetes mellitus: from basic discovery to therapeutics development | |
| Forst et al. | Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes |